Treace Medical Concepts, Inc. (TMCI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Investors Are Invited To Join The Schall Law Firm's Inquiry Into Treace Medical Concepts Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Treace Medical Concepts Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lost Money on Treace Medical Concepts, Inc. (TMCI)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business.
TMCI ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Treace Medical Concepts, Inc.
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business.
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Treace Medical Concepts Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - TMCI
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business.
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Encourages Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts Inc (TMCI) Q2 2024 Earnings Call Transcript
Treace Medical Concepts Inc (TMCI) Q2 2024 Earnings Call Transcript
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.20 per share a year ago.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
